Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CTFA guidelines

This article was originally published in The Rose Sheet

Executive Summary

The Cosmetic, Toiletry and Fragrance Association is requesting public comments on two new and one revised Safety Evaluation Guidelines by July 8, CTFA announces. The two new guidelines for genotoxicity and reproductive and developmental toxicity testing describe both in vivo and in vitro models, while the revised guidelines on photoirritation/photoallergy include in vivo, in vitro and clinical test methods, association notes. CTFA Safety Evaluation Guidelines "provide manufacturers with guidance regarding the use of preclinical and clinical safety testing as means to substantiate the safety of both ingredients and finished cosmetic products"...

You may also be interested in...



CTFA guidelines

The Cosmetic, Toiletry and Fragrance Association is requesting comments on a new Safety Evaluation Guideline on in vitro test methods for evaluating skin absorption; comments are due by Sept. 25. The association's guidelines "provide manufacturers with guidance regarding the use of preclinical and clinical safety testing as a means to substantiate the safety of both ingredients and finished cosmetic products." In June, CTFA requested comments on two new guidelines for genotoxicity and reproductive and developmental toxicity testing as well as revised guidelines on photoirritation/photoallergy (1"The Rose Sheet" June 26, 2006, In Brief)...

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014028

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel